Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease and the fourth most common disease-related mortality worldwide [
1,
2]. The 5-year survival is approximately 6 %, and only 20 % of patients present with resectable disease [
3,
4]. Few PDAC cases (less than 10 %) are diagnosed at early stages [
5], largely due to the absence of specific symptoms, and as such patients often present with advanced stage disease. Hence, the identification of novel prognostic indicators has become a major topic of interest to the PDAC research community at large.
The discoidin domain receptor 1 (DDR1) belongs to a subfamily of Receptor tyrosine kinases (RTKs) characterized by the presence of an extracellular discoidin homology domain that function to modulates cell proliferation and differentiation. DDRs are non-integrin collagen receptors composed of two types, DDR1 and DDR2, independently activated by receptor-specific collagens binding at the discoidin domain [
6]. DDR1 can be alternatively spliced into five isoforms (DDR1a-e). Recently, studies have suggested DDR1 participates in several critical cell processes including: adhesion, migration, proliferation, and invasion [
7‐
9]. Moreover, expression of DDR1 is known to be dysregulated in multiple human cancers such as lung, breast, hepatic, and ovary cancers, suggesting a previously unappreciated role of DDR1 in tumor formation and progression [
10‐
13]. In PDACs, however, the role of DDR1 remains to be uncharacterized.
In this retrospective study, we examined the expression pattern of DDR1 at the mRNA and protein level and explored the relationship of DDR1 expression with clinicopathologic parameters, including overall survival. We found that the expression of DDR1 was associated with poor prognosis of Chinese PDAC patients.
Materials and methods
Ethics statement
This research was approved by the Ethics Committee of Ren Ji hospital, School of Medicine, Shanghai Jiao Tong University, and written informed consent was obtained from each patient involved in this study.
Patients and tissue specimens
We retrospectively analyzed clinical and pathological characteristics of 205 patients who had resectable infiltrating PDAC and underwent surgical resection at the Biliary-Pancreatic Department of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, China, from January 2002 to June 2014 (see Table
1). Patients who had history of other solid tumors, received preoperative chemotherapy, radiotherapy or other anticancer therapies were excluded from this study. Standard pancreatectomy was undergone with lymph node dissection in patients who had no evidence of distant organ metastasis. Routine chemotherapy with gemcitabine had been given to all patients after operation, but no radiation treatment was done in any of the patients included in our study [
14]. An additional 30 fresh frozen tissues of PDAC and corresponding adjacent non-tumor tissues (located more than 2 cm apart from the tumor tissue in each case) were also obtained from the same department [
15]. The diagnosis was confirmed by two clinical pathologists.
Table 1
Association between DDR1 expression and clinicopathologic features in patients with PDAC
Age (years) | | | | |
Mean (years) | 65.19 | 66.82 | 62.69 | 0.374 |
< 65 | 107 | 65 | 42 | 0.826 |
≥ 65 | 98 | 61 | 37 | |
Gender | | | | 0.891 |
Male | 117 | 74 | 43 | |
Female | 88 | 52 | 36 | |
Tumor location | | | | 0.273 |
Head | 139 | 89 | 50 | |
Body/tail | 66 | 37 | 29 | |
Size | | | | 0.551 |
≤ 2 cm | 27 | 18 | 9 | |
> 2 cm | 178 | 108 | 70 | |
Tumor differentiation | | | | 0.054 |
Well | 11 | 10 | 1 | |
Moderate/poor | 194 | 116 | 78 | |
T classification | | | | 0.697 |
T1 | 11 | 8 | 3 | |
T2 | 31 | 18 | 13 | |
T3 | 125 | 73 | 52 | |
T4 | 38 | 20 | 18 | |
N classification | | | | 0.858 |
Absent | 136 | 83 | 53 | |
Present | 69 | 43 | 26 | |
AJCC stage | | | | 0.949 |
Stage I | 38 | 20 | 18 | |
Stage II | 135 | 73 | 62 | |
Stage III | 21 | 10 | 11 | |
Stage IV | 14 | 7 | 7 | |
Liver metastasis | | | | 0.560 |
Absent | 191 | 118 | 73 | |
Present | 14 | 8 | 6 | |
Vascular invasion | | | | 0.801 |
Absent | 177 | 109 | 68 | |
Present | 28 | 17 | 11 | |
Vital status | | | | 0.912 |
Dead | 172 | 106 | 66 | |
Alive | 33 | 20 | 13 | |
RNA extraction and real-time quantitative PCR (RT-qPCR)
Total RNA from primary tumor and adjacent non-tumor tissue samples was isolated with Trizol reagent (Takara, Japan), and reversely transcribed through PrimeScript RT-qPCR kit (Takara, Japan) according to the manufacturer’s instructions [
16]. RT-qPCR was performed using a 7500 RT-qPCR system (Applied Biosystems, Inc. USA) with a 15-μl PCR mix containing 0.5 μl of cDNA, 7.5 μl of 2*SYBR Green master mix (Invitrogen, Carlsbad, California, USA), and 200 nM of the appropriate primers (Invitrogen, Carlsbad, California, USA). Primer sequences set for DDR1 detection were as follows: forward primer: 5’-GCGTCTGTCTGCGGGTAGAG-3’, reverse primer: 5’-ACGGCCTCAGATAAATACATTGTCT-3’. The relative levels of mRNA expression were calculated based on the difference between amplification of DDR1 and β-actin RNA (forward: 5’-ACTCGTCATACTCCTGCT-3’, reverse: 5’- GAAACTACCTTCAACTCC-3’) using the 2
-ΔΔct method [
17]. To minimize technical (run-to-run) variation between the samples, all samples were analyze d in the same run for both target genes and reference genes. All experiments were performed three times with three technical replicates.
Western blotting analysis
Western blotting was performed as previously described [
18]. The DDR1 antibody was purchased from Proteintech Inc. and species-specific secondary antibody was purchased from Cell Signaling, Beverly, MA. Bound secondary antibodies were detected by Odyssey imaging system (LI-COR Biosciences, Lincoln, NE).
Tissue microarray (TMA) construction
Tissue microarrays (TMA) were constructed using diameter of 1.5-mm cores including 205 cases of matched tumor and non-tumor tissues specimens. After screening and marking representative spots of tissues, the tissues were punched out and squeezed into the paraffin array blocks.
Immunohistochemical (IHC) staining and scoring
Immunohistochemical staining was performed on a tissue microarray (TMA) containing 205 paired PDAC samples as previous described [
3]. Scoring was calculated according to the sum of the percentage of positively stained tumor cells: 0–5 % scored 0; 6 %–35 % scored 1; 36 %–70 % scored 2; more than 70 % scored 3 and the staining intensity: no staining scored 0, weakly staining scored 1, moderately staining scored 2 and strongly staining scored 3, respectively. The final score was designated as low or high expression group using the percentage of cells staining positive multiplied by the staining intensity as follows: “-” for a score of 0–1, “+” for a score of 2–3, “++” for a score of 4–6 and “+++” for a score of > 6; low expression was defined as a total score < 4 and high expression with a total score ≥ 4. These scores were determined independently by two senior pathologists. The scoring by the pathologists was done in a blinded manner.
Follow-up
The postoperative follow-up included clinical and laboratory examinations. OS, a measure of prognosis, was defined as the time from the date of surgery to the date of death or the last follow-up examination.
Statistical analysis
All statistical analyses were performed using SPSS 19.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5 (San Diego, CA) software. DDR1 mRNA in the tumor and adjacent non-tumor tissue samples were compared using a paired-samples
t test. The
Chi-square test and
Fisher’s exact probability method was used to analyze the relationship between DDR1 expression and clinicopathological characteristics. Survival curves were evaluated using the Kaplan-Meier method, and differences between survival curves were tested by the log-rank test. Cox proportional hazards regression model was used to examine univariate and multivariate hazard ratios for the study variables. Only significantly different variables in univariate analysis including DDR1 expression level, Age, N classification, Liver metastasis were entered into the next multivariate analysis [
19]. A two-sided
P-value < 0.05 was considered statistically significant.
Discussion
Previously studies have identified DDR1 is overexpressed in various human invasive tumors including lung, breast, hepatic, and ovary cancers, highlighting its possible role in tumor initiation, maintenance or progression [
10‐
13]. In the present study, DDR1 expression and its association with clinicopathological features including prognosis were investigated across a cohort of Chinese PDAC patients.
We determined that DDR1 expression was increased in Chinese PDAC patients at both the mRNA and protein level. These findings are supported by non-overlapping data from an Oncomine database, which highlights the same trends in PDAC. We expanded our analysis to a non-overlapping cohort of 205 patients and determined that DDR1 expression was upregulated in 126/205 PDAC specimens. Elevated DDR1 expression has also been reported in: (i) 52.2 % of hepatocellular carcinoma samples [
11]; (ii) 61.0 % of non-small cell lung cancer [
21]; and (iii) 63 % of serous ovarian cancer tissues [
13]. The overexpression of DDR1 in these different human cancers support the hypothesis that DDR1 may impact tumorigenesis and/or tumor progression.
Previous studies indicated that DDR1 could promote tumor progression by inducing cell adhesion and differentiation, which might be due to: (i) coexpressing with adhesion molecules [
22]; (ii) promoting epithelial-mesenchymal transition (EMT) [
21,
23]; (iii) participating in functional interaction of Notch1 and NF-κB pathway [
24,
25]. Furthermore, survival analysis in our study revealed that PDAC patients with high DDR1 expression levels had significantly shorter survival times than those with low expression levels. Univariate analyses showed that increased DDR1 expression was significantly associated with the overall survival rate in PDAC patients. Multivariate analysis demonstrated that DDR1 expression, together with some traditional prognostic factors, such as age, N stage and liver metastasis, were independent risk factors in the prognosis of PDAC patients. These results suggested that DDR1 may represent a novel prognostic marker for PDAC patients.
The precise molecular mechanisms through which DDR1’s impacts on tumor development and differentiation have yet to be elucidated. DDR1 presents 15 tyrosine residues in cell’s cytoplasmic regions, which are potential sites for phosphorylation and receptor activation by different types of collagens [
6,
12,
26]. It has been shown that over-expression of DDR1 increased the migration and invasion of hepatoma cells
in vitro, which implicated a role of DDR1 in tumor progression and metastatic dissemination [
27]. Reduced or absent DDR1 expression
in vivo leads to defects in placental implantation and development of mammary gland [
28], while Miao et al.[
21] demonstrated that DDR1 expression promoted epithelial-to-mesenchymal transition and contributed to non-small-cell lung cancer cells migration and invasion. The signaling pathways contributed by DDR1 upon cell-matrix interaction remain elusive and need further investigation.
In conclusion, this study demonstrated that DDR1 might serve as a novel prognostic biomarker in PDAC. Importantly, the molecular mechanisms underlying the relationship described above require clarification. Further studies are needed to investigate the molecular pathways involved in the regulation of DDR1, to improve our understanding and explore the possible therapies.
Acknowledgements
This study was supported by the National Natural Science Foundation of China (Grant No. 81401931) and the Young Medical Doctors Training and Funding Project of Shanghai Municipal Commission of Health and Family Planning. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Rong Hua and Yong-Wei Sun designed the research; Xueliang Fu, Dejun Liu, Jiao Li and Junfeng Zhang analysed the data; Yanmiao Huo, Minwei Yang, Wei Liu and Jianyu Yang performed the research and wrote the paper. All authors read and approved the final manuscript.